Pharmacokinetics/dynamics of Ciao, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 286, Issue 2, 1998, Pages 925-930

  Gobburu, Jogarao V S ^a,c   Tenhoor, Christopher ^b   Rogge, Mark C ^b   Frazier Jr , Donald E ^b,d   Thomas, David ^b,e   Benjamin, Chris ^b   Hess, Donna M ^b   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b BIOGEN   (United States)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^d Pfizer Central Research   (United States)

^e Tanox Biosystems Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 5C8; TETANUS TOXOID; UNCLASSIFIED DRUG; IMMUNOSUPPRESSIVE AGENT; LIGAND;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONKEY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; ANIMAL; BIOLOGICAL MODEL; HUMAN; IMMUNOLOGY; MACACA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIGANDS; MACACA FASCICULARIS; MODELS, BIOLOGICAL; TETANUS TOXOID;

EID: 0032219621     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Arizono H, Sugano T, Kaida S, Shibusawa K, Karasawa Y, Esumi Y, Kondo S and Kiyoki M (1994) Pharmacokinetics of new human monoclonal antibody against cytomegalovirus. Arzneimittelforschung 44(II):909-913.
2. Cammarata A, Smith J and Willet NP (1975) Pharmacokinetic model for a primary antibody response. J Pharm Sci 8:1325-1328.
3. Davis CB, Hepburn TW, Urbanski JJ, Kwok DC, Hart TK, Herzyk DJ, Demuth SG, Leland M and Rhodes GR (1995) Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. Drug Metab Dispos 23:1028-1036.
4. Dayneka NL, Garg V and Jusko WJ (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457-478.
5. Durie FH, Foy TM, Masters SR, Laman JD and Noelle RJ (1994) The role of CD40 in the regulation of humoral and cell-mediated immunity. Immunol Today 9:406-411.
6. 111In-labeled monoclonal antibody in humans. Cancer Res 47:3328-3336.
7. Everitt DE, Davis CB, Thompson K, DiCicco R, Ilson B, Demuth SG, Herzyk DJ and Jorkasky DK (1996) The pharmacokinetics, antigenicity and fusion-inhibition activity of R. S. H.Z19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J Infect Dis 174:463-469.
8. 2a anti-CD4 monoclonal antibody) in human organ transplantation: Pharmacokinetics and peripheral pharmacodynamics. Transplant Proc 25:800-801.
9. Hollenbaugh D, Mischel-Petty N, Edwards CP, Simon JC, Denfeld RW, Kiener PA and Aruffo A (1995) Expression of functional CD40 by vascular endothelial cells. J Exp Med 182:33-40.
10. Larsen CP, Alexander DZ, Hollenbaugh D, Elwood ET, Ritchie SC, Aruffo A, Hendrix R and Pearson TCC (1996) CD40-gp39 interactions play a critical role during allograft rejection. Transplantation 61:4-9.
11. Mohan C, Shi Y, Laman JD and Datta SK (1995) Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J Immunol 154:1470-1480.
12. Parker DC, Greiner DL, Phillips NE, Appel MC, Steele AW, Durie FH, Noelle RJ, Mordes JP and Rossini AA (1995) Survival of mouse pancreatic islet allografts in recipients treated with allogenic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci USA 92:9560-9564.
13. Stout RD, Buttles J, Xu J, Grewal IS and Flavell RA (1996) Impaired T cell-mediated macrophage activation in CD40 ligand-deficient mice. J Immunol 156:8-11.
14. Wallace KH and Thompson RA (1991) Immunointervention in Man. p 16, Oxford University Press, New York NY.